Trial no.:
|
PACTR201811844846658 |
Date of Approval:
|
08/11/2018 |
Trial Status:
|
Registered in accordance with WHO and ICMJE standards |
|
TRIAL DESCRIPTION |
Public title
|
The Combined Effect of Extracorporeal Shockwave Therapy and Integrated Neuromuscular Inhibition Technique on Myofascial Trigger Points of Upper Trapezius |
Official scientific title |
The Combined Effect of Extracorporeal Shockwave Therapy and Integrated Neuromuscular Inhibition Technique on Myofascial Trigger Points of Upper Trapezius |
Brief summary describing the background
and objectives of the trial
|
The upper trapezius (UT) muscle runs between the cervical and thoracic spines and upper medial border of the scapula. The UT has an important role in optimizing scapular elevation and upward rotation control during shoulder abduction. However, overuse of the UT muscle during shoulder movements can interfere with scapular alignment and the movement pattern can lead to specific errors in choosing an appropriate movement strategy. Myofascial trigger points (MTrPs) are the main sources of musculoskeletal pain in about 30-85% of patients, and these knots have detrimental effects on patient's social activities and quality of life. The extracorporeal shock wave therapy (ESWT) is a non-invasive treatment which has recently come into use for musculoskeletal disorders. In patients with non-specific neck pain (NS-NP) integrated neuromuscular inhibition technique to the treatment of MTrPs has proven to be more beneficial in relieving pain, reducing stiffness, and improving functional ability. So the purpose of the study is to measure the combined effect of extracorporeal shockwave therapy and integrated neuromuscular inhibition technique on myofascial trigger points of upper trapezius. A pilot study will be conducted to calculate sample size. The subjects of both genders with age ranging from 18 to 30 will be allocated randomly into three equal groups A,B and C. Outcome measures will include: Pressure Pain Threshold(PPT)will be measured by electronic algometer, Pain intensity will be measured by Visual analogue scale(VAS), Sympathetic skin response(SSR) and Neuromuscular junction response(NMJR) will be measured by electromyography instrument. The assessment will be done before and after treatment. |
Type of trial |
RCT |
Acronym (If the trial has an acronym then please provide) |
UT MTrPs ESWT INIT NSNP PPT VAS SSR NMJR |
Disease(s) or condition(s) being studied |
Musculoskeletal Diseases |
Sub-Disease(s) or condition(s) being studied |
|
Purpose of the trial |
Treatment: Other |
Anticipated trial start date |
01/12/2018 |
Actual trial start date |
|
Anticipated date of last follow up |
01/12/2019 |
Actual Last follow-up date |
|
Anticipated target sample size (number of participants) |
60 |
Actual target sample size (number of participants) |
|
Recruitment status |
Not yet recruiting |
Publication URL |
|
|